This NEW report provides detailed insights into the efficacies and applications of patent protection, helping you to optimise and sustain your strategies to maximise product revenues...
Business Intelligence for the Pharmaceutical Industry

**Business Insights'** portfolio of healthcare management reports are designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions.

The **strength of our healthcare research and analysis** is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry.

Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including **strategy, industry analysis, market outlook, new business opportunities** and **strategic insight**.

Some key findings from this report...

- **ANSA reviews** are most effectively delayed by pursuing litigation for patent infringement.
- **A recently established US Supreme Court ruling** will extensively influence future patenting strategies, having been formed in the April 2007 US Supreme Court ruling on patentability involving KSR International Co -v- Teleflex Inc.
- **Contingency plans** can effectively counter failed or defective patent strategies, as shown in the Claritin and Prozac case studies.
- **Successful patent protection strategies** can vastly enhance the sustainability of product franchise revenues, significantly exceeding the lifetimes of basic patents. Prominent examples include AstraZeneca’s Losec and Nexium, and Amgen’s epoetin alfa.
- **Holistic investigation of a firm’s ‘Freedom to Operate’** is necessary prior to resource committal in product development or commercialization.

---

"The decline in revenues once patent protection expires is now expected to be precipitous, as illustrated by the more recent example of Merck & Co.’s Zocor. Merck’s US market exclusivity for this product expired on 23 June 2006, after the patent lifetime had been extended for an extra six months for pediatric exclusivity. Quarterly sales of the branded drug sharply declined, from $3.1 billion in 2005 to $1.9 billion in 2006, while sales of the generic simvastatin in the same period reached $1.4 billion... "

Source: Norman Consulting, Business Insights
Patent Protection Strategies

As new drug developments continue to necessitate increasingly high investments, successfully protecting revenue sustainability from the threat of low cost substitutes is reliant upon fully harnessing the efficacies of the patent system. In a market environment where competition from generics companies is becoming increasingly aggressive and the patenting of therapeutics is continually subject to impending legislative change, understanding how to effectively reassess, develop and exploit patent protection strategies is essential in facilitating enhanced market exclusivity and revenue returns over the lifecycles of new drugs.

Patent Protection Strategies: Maximising product revenues is a new report published by Business Insights, examining the need for optimising and sustaining the patent protection of novel products. The report explores the best methods of exploiting legislation to maximise revenue generation and protecting the considerable investments associated with innovations. It will also examine the both the offensive and defensive tactics that can develop product lifecycle strategies, through the refinery of organisational patent protection in tandem to encumbering the market entry of generic substitutes.

Use this report to understand how to successfully develop and apply patent protection strategies, exploit legislation effectively and secure the lifecycles of your innovations to maximise revenue returns...

Top five reasons to order your copy today

- **Strengthen product protection by tailoring patent options** to the individual specifications of your products more effectively.
- **Create a multi-strategy approach to defend your products and their revenues**, as detailed within this report.
- **Enhance the efficacy of your patenting policy and opportunity management** with explicit insights into the impending legislative changes concerning biosimilars and pediatric exclusivity, in addition to fallout analysis from the April 2007 Supreme Court ruling.
- **Integrate your patent protection and product lifecycle strategies with greater fluency**, and reap the long term revenue benefits that improved synchronicity will afford.
- **Improve your current patenting practises by benchmarking case histories**, and augment your organisation’s approach to achieve effective and successful strategy application.

“AstraZeneca’s protection of its high value ulcer franchise is probably the most successful such example to date of sustaining revenues from a high value franchise after patent expiration. The financial success of this strategy is clearly illustrated in the above chart, note how the value of this combined franchise has barely changed throughout the period 2000 to 2006...”
Key issues examined in this report...

**Dependence of major companies’ 2006 revenues on blockbuster products**

- **Recouping drug development costs.** The acute importance of sustainable market exclusivity for new drugs, through the use of patents and other legislative methods, in relation to recovering development costs and optimising revenue returns.

- **US Supreme Court ruling.** The scope of product patentability and patent protection strategies in general are widely expected to experience drastic changes as a result of the April 2007 ruling.

- **Growing market prevalence of authorised generics.** An industry-wide debate has been evoked over the increasing use of authorised generics, based upon concerns over validity and consumer benefit.

- **Biosimilar legislation.** In June 2007, American Congress established a legal framework concerning the market admission of biosimilar products.

- **Implications of declining NCE’s.** Diminishing NCE’s highlight the importance of maximising patent protection for new drug entrants.

Your questions answered...

**Novel Therapeutic Entities Approved by the FDA, 2000-2006**

- How can the nominal 20 year period of patent protection be most effectively extended?

- What frameworks can be applied to formulate a holistic market strategy incorporating patent and product lifecycle considerations?

- How can the market entry of generic substitutes be delayed?

- Do significant differences exist between the patenting methods practised across the major markets?

- How may legislative changes impact upon future patent strategies and what areas of new legislation are currently under discussion?

- What are the most effective patenting techniques and how can they be applied to maximise the sustainability of product revenues?
Chapter 1: The need for patent protection

The impact of generics

The need for an effective defense of a company’s patents is highlighted by the rapid loss of revenues that results when cheaper generic substitutes become available. Although this has always been a problem for the suppliers of branded pharmaceutical products, it has become a more critical issue with the emergence of blockbuster products.

The consequent revenue losses can be disastrous for a company’s cash flow and, if a company is over reliant on a single product, could even prove catastrophic.

The first clear example of how this could impact upon revenues is provided by the example of Eli Lilly’s Prozac (fluoxetine). In 2000 global sales of Prozac were $2.6 billion of which $2.2 billion was generated in the US. Eli Lilly believed that it had patent protection for Prozac, in the US, until 2004, thereby preventing the availability of cheaper generic substitutes until that time. And Lilly’s strategy for defending this franchise was based upon that assumption.

However, the validity of this patent was challenged by Barr Laboratories and, following a series of court rulings in Barr’s favor it was determined that Lilly’s market exclusivity for fluoxetine would end on 2 August 2001. Barr had anticipated that it would win the case and had stockpiled fluoxetine enabling it to flood distribution channels rapidly, in order to take full advantage of the 180 day exclusivity granted to the first generic product. This led to a much sharper erosion of Prozac sales than anticipated by either Eli Lilly or by market analysts. Prozac revenues declined by 66% in the final quarter of 2001, continued to fall through 2002, as shown in Figure 1.4, and then more slowly thereafter.

Revenues from generic fluoxetine products also declined as various suppliers battled for cost leadership of this segment. The failure of Eli Lilly’s patent strategy cost the company around $6 billion in lost revenues. The decline in revenues once patent protection expires is now expected to be precipitous as illustrated by the more recent example of Merck & Co.’s Zocor (simvastatin). Merck’s US market exclusivity for this product expired on 23 June 2006 after the patent lifetime had been extended for an extra six months for pediatric exclusivity.

Order this report today to find out more...
Table of Contents

EXECUTIVE SUMMARY
- The need for patent protection
- Current patent protection mechanisms
- Offensive strategies
- Case Histories
- Optimizing Revenue Returns
- Future outlook

Chapter 1: The need for patent protection
- Summary
- Introduction
  - The costs of drug development
  - The drug lifecycle
  - The need to optimize returns from successful drugs
  - The dependence on blockbuster revenues
  - The impact of generics
  - Aggressive generic companies

CHAPTER 2: CURRENT PATENT PROTECTION MECHANISMS
- Summary
- Introduction
- Patent basics
- Requirements for a therapeutic patent
- Four types of pharmaceutical patent
- Legal patent frameworks
  - United States
  - Europe/PCT
  - Japan
  - Other markets
- Patent term extensions
  - US patent term extensions
  - Supplementary Protection Certificates
  - Japanese Patent term extensions
  - Pediatric exclusivity
- Orphan Drug legislation
- Regulations for market entry of generics
  - United States
  - Hatch Waxman
  - ANDAs
  - Paragraph IV challenges
  - Europe
  - Japan
- Biological Products and Biosimilars
  - United States
  - Europe
- Freedom to operate

CHAPTER 3: OFFENSIVE STRATEGIES
- Summary
- Introduction
- Filing strategies
  - Early or late filing?
  - Overlapping claims
  - Broad claims or narrow claims?
- Exploitation of term extension legislation
- Product patents
  - Subsidiary patents
  - Crystalline form patents
  - Salt and solvate patents
  - Enantiomer patents
  - Prodrug and antedrug patents
- Process patents
- Formulation patents
  - Improved formulations
  - Drug Combinations
  - "Obvious" antihypertensive combinations
  - Advair
  - Antidiabetic agents
- New delivery routes
- Method of Use patents
CHAPTER 4: DEFENSIVE STRATEGIES
- Summary
- Introduction
- Patent infringement suits
  - Mechanism
- Authorized generics
- OTC switches
- Orange Book delisting
- Research Disclosures

CHAPTER 5: CASE HISTORIES
- Summary
- Introduction
- Prozac
- Losec and Nexium
- Epogen v Dynepo
- Plavix
  - Legal challenges
  - Impact of generic clopidogrel

CHAPTER 6: OPTIMIZING REVENUE RETURNS
- Summary
- Introduction
- Lifecycle initiatives
- Franchise development
  - Follow on products
  - Secondary patents
  - Prodrugs
- Portfolio development
- Competing with generics

CHAPTER 7: FUTURE OUTLOOK
- Summary
- Introduction
- Changes in drug development
  - Impact of technology
  - Tougher project goals
- Legislative issues
  - KSR International Co. v. Telex
    Inc (US Supreme Court)
- Biologicals

FIGURES
- Novel Therapeutic Entities Approved by the FDA, 2000-2006
- Schematic drug revenue life cycle
- Dependence of major companies’ 2006 revenues on blockbuster products
- Quarterly US sales of Zocor 2005-2006
- US sales of OTC and Prescription Claritin, 2000-2006
- Variation in number of SPCs granted in EU countries, 2003
- Variation in number of SPCs granted in EU countries, 2003

TABLES
- Drugs generating 2006 revenues in excess of $3 billion
- Possible term extensions in major markets
- Selected high revenue generating Orphan drugs
- Orphan drug legislation in the major markets
- Amgen’s key Epogen patents

Impact of offensive strategies on drug revenue life cycle
Primary claims of two key patents relating to paroxetine
Impact of defensive strategies on drug revenue life cycle
Timeline of from Paragraph IV ANDA filing
US sales of Paxil, an authorized generic and a competing generic August 2003- June 2004
US Sales revenues of Schering-Plough’s major anti-histamines 2000-2006
Revenues from AstraZeneca’s antiulcer franchise 1999-2006
US Sales of Wellbutrin and generic bupropion 1999-2006
Global sales of Adalat formulations 1975-2000